Abstract: In a method of producing an add-on part of a drive, one circuit board of multiple planar circuit boards, which have electrical conductor tracks with electrical connections, is provided with a centrally arranged opening for passage of a shaft. The circuit boards are populated with electrical and/or electronic components, and the populated electrical and/or electronic components and wiring are electrically tested. Segments made of a material with high thermal conductivity are arranged on at least two of the multiple circuit boards such that a bending process in a region of the electrical connections between the at least two circuit boards causes the segments to form an approximately peripherally closed cover. Lids are arranged on open sides of the cover to realize a closed housing arrangement.

Abstract: On the basis of provided product knowledge, a software object which functions as a digital twin of a technical product is created. The product knowledge is available in an automatically processable form and comprises, as object variants, data records having data for different variants of at least one component of the technical product. The object variants are each assigned an object variant classification, which functions as a unique identifier, as well as geometric data and positional data. Each object variant, the object variant classification of which matches a predetermined or predeterminable article code, is processed as belonging to the digital twin. For each object variant belonging to the digital twin, the, or each, geometric object described by the geometric data of the object variant is positioned corresponding to the positional data of the object variant.

Abstract: A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.

Abstract: A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.

Abstract: A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period.